Ritonavir co-administration boosted the pharmacokinetics of ABT-450 with ABT-450 Cmax & AUC increased 28-fold & 48-fold: therefore, ABT-450 is being developed with low-dose RTV to enhance exposure & allow once-daily dosing. From day i through day 4, the mean maximum HCV RNA decreases from baseline was 4.02 log10 IU/mL for subjects receiving ABT-450/r.
